![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SWISS DRUG DELIVERY FIRM LICENSES FAST-ACTING DICLOFENAC PRODUCTS TO U.S. BASED PROETHIC PHARMACEUTICALS
SWISS DRUG DELIVERY FIRM LICENSES FAST-ACTING DICLOFENAC PRODUCTS TO U.S. BASED PROETHIC PHARMACEUTICALS
September 13, 2005
Applied Pharma Research (APR), a Swiss-based R&D firm that specializes in enhancing drug delivery, and ProEthic Pharmaceuticals Inc., announced today that APR has granted an exclusive license to ProEthic to develop and market two fast-acting formulations of diclofenac potassium in the U.S. and Canada. Diclofenac potassium, commonly referred to as an "NSAID" (non-steroidal anti-inflammatory drug), was originally marketed by Novartis in the 1990's for the treatment of rheumatoid and osteoarthritis, dysmenorrhea and mild to moderate pain.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1053094XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct